GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders

 GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders

BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) — Greater Cannabis Company, Inc. (GCANRx or the Company) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation t…